Last updated: 20 March 2020 at 8:39pm EST

Fund Management Ltd.Okumus ... Net Worth




The estimated Net Worth of Fund Management Ltd.Okumus ... is at least $397 Million dollars as of 18 July 2019. Fund Okumus owns over 30,000 units of MiMedx Inc stock worth over $90,145,589 and over the last 8 years Fund sold MDXG stock worth over $306,538,746.

Fund Okumus MDXG stock SEC Form 4 insiders trading

Fund has made over 17 trades of the MiMedx Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Fund bought 30,000 units of MDXG stock worth $129,000 on 18 July 2019.

The largest trade Fund's ever made was selling 9,000,000 units of MiMedx Inc stock on 31 August 2017 worth over $223,110,000. On average, Fund trades about 1,104,172 units every 61 days since 2016. As of 18 July 2019 Fund still owns at least 14,563,100 units of MiMedx Inc stock.

You can see the complete history of Fund Okumus stock trades at the bottom of the page.



Insiders trading at MiMedx Inc

Over the last 15 years, insiders at MiMedx Inc have traded over $15,165,698 worth of MiMedx Inc stock and bought 1,553,718 units worth $4,191,559 . The most active insiders traders include Fund Management Ltd.Okumus ..., Steve Gorlin, and Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of $487,865. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth $162,029.



What does MiMedx Inc do?

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.



What does MiMedx Inc's logo look like?

MiMedx Group, Inc logo

Complete history of Fund Okumus stock trades at Endurance International Inc and MiMedx Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
18 Jul 2019 Fund Management Ltd.Okumus ...
Buy 30,000 $4.30 $129,000
18 Jul 2019
14,563,100
17 May 2019 Fund Management Ltd.Okumus ...
Sale 5,020,681 $1.49 $7,480,815
17 May 2019
9,582,719
15 May 2019 Fund Management Ltd.Okumus ...
Buy 114,200 $4.83 $551,586
15 May 2019
14,533,100
10 May 2019 Fund Management Ltd.Okumus ...
Buy 411,178 $2.53 $1,040,280
10 May 2019
14,418,900
7 May 2019 Fund Management Ltd.Okumus ...
Buy 403,123 $5.08 $2,047,865
7 May 2019
14,007,722
22 Jan 2019 Fund Management Ltd.Okumus ...
Sale 1,991,700 $2.81 $5,596,677
22 Jan 2019
10,533,355


MiMedx Inc executives and stock owners

MiMedx Inc executives and other stock owners filed with the SEC include: